Table 4.
Tumor response of different treatment modalities (n=26)
| Treatment modalities | Patients (n, %) | ORR (%)a | ORR (%)b |
|---|---|---|---|
| TKI+PD-1/PD-L1 monoclonal antibody | 1 (3.8) | 1 (100) | 1 (100) |
| Sorafenib + Sintilimab | 1 | 1 (100) | 1 (100) |
| Locoregional therapies + TKI | 4 (15.4) | 1 (25) | 3 (75) |
| TACE + Lenvatinib | 3 | 0 (0) | 1 (33.3) |
| TACE + Radiotherapy+ Lenvatinib | 1 | 0 (0) | 1 (100) |
| Locoregional therapies +TKI + Anti-PD-1 | 21 (80.8) | 10 (47.6) | 17 (81) |
| HAIC + Lenvatinib + Camrelizumab | 12 | 5 (41.7) | 8 (66.7) |
| HAIC + Apatinib + Camrelizumab | 3 | 2 (66.7) | 3 (100) |
| TACE + Sorafenib +Sintilimab | 1 | 0 (0) | 1 (100) |
| TACE + Sorafenib + Camrelizumab | 2 | 2 (100) | 2 (100) |
| TACE + Lenvatinib + Camrelizumab | 1 | 0 (0) | 1 (100) |
| TACE + Apatinib + Camrelizumab | 2 | 1 (50) | 2 (100) |
aRECIST v1.1
bmRECIST